Episodes (Page 7)
✨
TC BioPharm CEO Bryan Kobel explains the advantages of gamma delta T cells (GDT) for cell therapy.
Bryan Kobel
✨
Poseida Therapeutics CEO Mark Gergen discusses the shift from AAV to nanoparticle delivery.
Mark Gergen
✨
Immatics' Michael Mehler explains new hybrid roles in autologous cell therapy clinical trials.
Michael Mehler
✨
Cartesian Therapeutics' Dr. Metin Kurtoglu discusses the move to allogeneic RNA cell therapies.
Metin Kurtoglu
✨
Encoded Therapeutics' Andy Stober addresses unique commercial manufacturing issues in gene therapy.
Andy Stober
✨
Anixa Biosciences CEO Amit Kumar details progress on a CAR-T therapy for ovarian cancer.
Amit Kumar, Ph.D
✨
Celyad Oncology CMO Dr. Charlie Morris discusses allogeneic versus autologous CAR-T therapies.
Charlie Morris
✨
Rocket Pharmaceuticals CEO Dr. Gaurav Shah discusses FDA clinical holds on gene therapy trials.
✨
BlueSphere Bio CEO Dr. David Apelian explains the challenges of treating solid tumor cancers.
David Apelian
✨
Cue Biopharma's Anish Suri explains novel injectable biologics for targeted T cell modulation.
Anish Suri
✨
Nina Hunter discusses regulatory pathways for gene therapies.
Nina Hunter, Ph.D
✨
Dr. Carsten Brunn on Selecta Biosciences' ImmTOR platform.
✨
Dr. Derrell Porter on diversity in biotech leadership.
Derrell Porter
✨
Dr. Michael Singer on RNA's advantages in cell therapy.
Michael Singer
✨
Robert Ang on Vor Biopharma's engineered HSCs.
Robert Ang
✨
Fernanda Copeland on patient advocacy in trials.
Fernanda Copeland
✨
Dr. Debora Barton on CAR-M technology.
Debora Barton
✨
Albert Gianchetti on gene therapy for CAD.
Albert Gianchetti
✨
Dr. Amy Nicole Nayar on patient engagement.
Amy Nicole Nayar
✨
Dr. Eric David on BridgeBio's gene therapy approach.
Eric David